Typical Presentation of LAST After Appropriately Dosed Ropivacaine
Even with appropriately calculated doses of ropivacaine, LAST most commonly presents with CNS symptoms (77-89% of cases), particularly seizures, followed by agitation, syncope, obtundation, and dizziness, though cardiovascular toxicity can occur in 32-55% of cases and may be life-threatening. 1
Clinical Presentation Pattern
The presentation of LAST does NOT always follow the "classic" textbook progression. According to case series analysis:
- Only 60% of cases follow the classic pattern of progressive neurologic symptoms culminating in seizures before cardiovascular collapse 2
- 40% present atypically with either:
- Substantially delayed symptoms after injection
- Isolated cardiovascular compromise without any CNS signs 2
CNS Manifestations (Most Common)
The neurologic symptoms include:
- Seizures (most frequent presentation)
- Agitation and excitation
- Syncope or loss of consciousness
- Obtundation
- Dizziness
- Perioral paresthesias and facial numbness 3, 4
- Diffuse tremors and spasticity 4
Cardiovascular Manifestations (Less Common but Life-Threatening)
When cardiovascular toxicity occurs, it presents as:
- Bradycardia (most common cardiovascular sign) 1
- Hypertension and tachycardia initially 5, 3
- Premature ventricular contractions
- Wide-complex tachycardia
- Asystole (12% of cases) 1
- Ventricular fibrillation or ventricular tachycardia (13% of cases) 1
- Circulatory collapse and refractory cardiogenic shock 1
Critical Nuances for Ropivacaine Specifically
Ropivacaine is less cardiotoxic than bupivacaine due to lower affinity and shorter binding duration to cardiac sodium channels 1. However, this does NOT eliminate risk:
- Large-volume fascial plane blocks (e.g., TAP blocks, ESPB) with ropivacaine can produce plasma concentrations high enough to cause neurotoxicity even at recommended doses 6, 7
- In one study of TAP blocks using 2.5 mg/kg ropivacaine, peak concentrations reached 1.82 μg/mL (mean), with maximum of 3.76 μg/mL, and three patients developed mild neurotoxicity symptoms 6
- Recent data shows approximately 5% of patients may reach arterial plasma concentrations above LAST cutoff levels after ESPB with 150 mg ropivacaine 8
High-Risk Scenarios for "Appropriate" Doses
Even calculated doses can cause LAST in:
- Uremic patients with reduced renal clearance 3
- Infants and elderly with altered metabolism 9
- Patients with decreased liver function 5
- Low cardiac output states 5
- Highly vascularized injection sites 3
- Lower body weight patients - fixed dosing (e.g., 150 mg regardless of weight) increases risk 8
Common Pitfall
The use of fixed doses rather than weight-based dosing is a major contributor to toxicity with "appropriate" doses. Body weight and BSA are significant predictors of ropivacaine exposure 8. A 150 mg dose may be appropriate for an 80 kg patient but excessive for a 50 kg patient.
Temporal Pattern
- Peak plasma concentrations typically occur at 20-30 minutes post-injection for fascial plane blocks 6, 8
- However, symptoms can be substantially delayed beyond this timeframe in up to 40% of cases 2
- Patients may progress rapidly from CNS toxicity to cardiotoxicity 1
Key Recognition Points
Watch for the progression pattern: CNS excitation → seizures → CNS depression → cardiovascular collapse, but remember this occurs in only 60% of cases. The other 40% may present with isolated cardiovascular collapse without warning CNS signs 2.
Bradycardia should raise immediate concern as it is the most common cardiovascular manifestation and may herald impending cardiovascular collapse 1.